Telix Pharmaceuticals Limited
Suite 401, 55 Flemington Road
North Melbourne, VIC, 3051
ABN: 85 616 620 369

For personal use only

Financial year ended
31 December 2021

Results for announcement to the market

Current Reporting Period:	31 December 2021
Previous Reporting Period:	Period from 1 January – 31 December 2020

Revenue and net profit (loss)

	Change	Change $000	Change %	2021 result $000
Revenue	Up	2,383	46%	7,596
Other income and expenses	Up	11,071	113%	20,855
Total income [(i)]	Up	13,454	90%	28,451
Loss from continuing operations after tax	Up	(35,623)	79%	(80,510)
Total comprehensive loss	Up	(37,436)	84%	(81,962)

(i) Total income is the sum of Revenue and other income and expenses.

Dividends
No dividend was proposed or paid. The Company is not yet profitable and therefore there can be no assurance that the Company will become profitable or will pay dividends in the near future. Should any dividends be paid in the future, no assurances can be given as to the level of franking credits attaching to such dividends.

	2021 Cents	2020 cents
Earnings/(loss) per share	(28.5)	(17.5)
Net tangible assets per share	(19.0)	6.4
Dividend per share	-	-

Brief explanation of income and loss
As a development-stage company, Telix Pharmaceuticals has recorded an operating loss for the year. The majority of expenses in the year relate to R&D activities for the Company's assets and development programs. The Company has recorded R&D tax incentive income for the year of $18,574,000 (2020: $12,318,000). The R&D tax incentive receivable has been determined based on a combination of eligible domestic and international expenditure of $42,965,000 (2020: $28,317,000) at a rate of 43.5c tax incentive rebate per eligible R&D dollar spent.

Statement of accumulated losses	2021 $000	2020 $000
Balance at the beginning of the year	(92,961)	(48,074)
Net loss attributable to members of the parent entity	(80,510)	(44,887)
Balance at end of the year	(173,471)	(92,961)

Audit report
This Appendix 4E (Final Report) is based on the audited financial statements for the year ended 31 December 2021 which are attached.

The Appendix 4E and Annual Report have been approved for release by the Board of Directors.